Andrew J Steele
Overview
Explore the profile of Andrew J Steele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
1106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brody J, Jorgensen Dr J, Belada D, Costello R, Trneny M, Vitolo U, et al.
Blood
. 2025 Jan;
PMID: 39792928
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of...
2.
Kater A, Owen C, Moreno C, Follows G, Munir T, Levin M, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200006.
PMID: 38319255
BACKGROUND: GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-venetoclax in older patients and/or those with comorbidities with previously untreated chronic lymphocytic leukemia (CLL). METHODS: We...
3.
Bryant D, Smith L, Rogers-Broadway K, Karydis L, Woo J, Blunt M, et al.
Leukemia
. 2023 May;
37(7):1454-1463.
PMID: 37169950
Chronic lymphocytic leukaemia (CLL) cells can express unmutated (U-CLL) or mutated (M-CLL) immunoglobulin heavy chain (IGHV) genes with differing clinical behaviours, variable B cell receptor (BCR) signalling capacity and distinct...
4.
Johnson P, Balasubramanian S, Hodkinson B, Shreeve S, Sun S, Srinivasan S, et al.
Blood Adv
. 2023 Jan;
7(10):2008-2017.
PMID: 36696540
Diffuse large B-cell lymphoma (DLBCL), with high coexpression of BCL2 and MYC proteins (DE lymphoma), is considered an adverse prognostic indicator associated mostly with non-germinal center B-cell-like (non-GCB) DLBCL. BCL2/MYC...
5.
6.
Arthur R, Wathen A, Lemm E, Stevenson F, Forconi F, Linley A, et al.
Cell Signal
. 2022 May;
96:110358.
PMID: 35597428
BTK inhibitors (BTKi) have dramatically improved outcomes for patients with chronic lymphocytic leukaemia (CLL) and some forms of B-cell lymphoma. However, new strategies are needed to enhance responses. Here we...
7.
Minton A, Smith L, Bryant D, Strefford J, Forconi F, Stevenson F, et al.
Explor Target Antitumor Ther
. 2022 Mar;
3:37-49.
PMID: 35309250
Aim: T-helper cells could play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL), a common B-cell neoplasm. Although CLL cells can present soluble antigens targeted from the...
8.
Taylor J, Wilmore S, Marriot S, Rogers-Broadway K, Fell R, Minton A, et al.
Cell Signal
. 2022 Mar;
94:110311.
PMID: 35306137
B-cell receptor (BCR) signaling plays a major role in the pathogenesis of B-cell malignancies and is an established target for therapy, including in chronic lymphocytic leukemia cells (CLL), the most...
9.
Wilmore S, Rogers-Broadway K, Taylor J, Lemm E, Fell R, Stevenson F, et al.
Cell Mol Life Sci
. 2021 Aug;
78(17-18):6337-6349.
PMID: 34398253
Signaling via the B-cell receptor (BCR) is a key driver and therapeutic target in chronic lymphocytic leukemia (CLL). BCR stimulation of CLL cells induces expression of eIF4A, an initiation factor...
10.
Linley A, Karydis L, Mondru A, DAvola A, Al Shmrany H, Cicconi S, et al.
Clin Cancer Res
. 2021 Aug;
27(20):5647-5659.
PMID: 34380642
Purpose: B-cell receptor (BCR) signaling is critical for the pathogenesis of chronic lymphocytic leukemia (CLL), promoting both malignant cell survival and disease progression. Although vital, understanding of the wider signaling...